drugset / Trial / NCT05860569
Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis
Non-randomizedSequentialOpen-labelTreatment
Summary
The study will evaluate safety and tolerance of intravenous delivery of GC304 gene therapy drug as a treatment of primary hypertriglyceridemic patients with previous onset of acute pancreatitis.
Timeline
- Start
- 2024-09-20
- Primary completion
- 2026-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC304 | Unknown | 1 vg/kg | Intravenous |
| Subject | GC304 | Unknown | 3 vg/kg | Intravenous |